Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

Bayer

Status: Completed

Conditions: Prostatic Neoplasms, Castration-Resistant

Treatments: Drug: Xofigo (Radium-223 dichloride, BAY88-8223)

Study type: Observational

Funder types: Industry

Identifiers

NCT02899104

18919

Details and patient eligibility

About

Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.

Full description

This is a chart review of 200 Xofigo patients to describe sequencing and characterize clinical parameters and patient determinants that drive physician decision making.

Enrollment: 200 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart.

• Patients were at least 18 years of age as of the first diagnosis for mCRPC.

• Patients must have received at least one intravenous injection of Radium-223 (Xofigo).

• First injection of Radium-223 must have started between periods

  1-January-2014 to 30-June-2014 or 15-November-2014 to present.

• Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose.

Exclusion criteria

• Patients who received Radium-223 as part in an interventional clinical trial
• Actively treated, or expect to be treated, in 6 months before last follow-up, for any other malignancy with the exception of non-metastatic skin cancer or low-grade superficial bladder cancer.

Trial design

200 participants in 1 patient group

Radium-223 dichloride

Description:

Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.

Treatment:

Drug: Xofigo (Radium-223 dichloride, BAY88-8223)